EGFR and non-small cell lung carcinoma: Moreover, preclinical data demonstrated that furmonertinib had an antitumor effect in Ba/F3 cell line expressing EGFR ex20ins, patient-derived xenograft models harboring EGFR ex20ins mutation and treatment-naïve NSCLC patients with EGFR ex20ins (Baohui Han, 2021; Das et al., 2021).